Pretransplant and posttransplant antibodies in human corneal transplantation.
The purpose of this study was to measure the association between antibody formation and endothelial corneal allograft reactions in 533 consecutive corneal graft recipients. The median follow-up time of these recipients was 732 days. Pretransplant panel-reactive antibodies were not found to be associated with endothelial corneal allograft reactions. Out of 533 recipients, 239 developed posttransplant antibodies during the course of this study. The formation of posttransplant antibodies was frequent in recipients with pretransplant antibodies and in HLA-A,-B-incompatible recipients. Posttransplant antibodies most often appeared within the first six months after transplantation whereas endothelial allograft reactions most often occurred later. Out of 65 recipients who developed PPRA and underwent an allograft reaction, 53 had a PPRA peak prior to, or at about the time of, the allograft reaction. Corneal allograft reaction events diagnosed during the second and third year after surgery were correlated with PPRA formation during the first year after grafting. The 36-month reaction-free survival rate of transplants was estimated at 72% in recipients with PPRA compared with 86% in recipients without PPRA (log rank P value = 0.002). Furthermore, posttransplant antibody formation altered the outcome of corneal allografts in both HLA-A and -B-compatible and -incompatible recipients. These findings suggest that posttransplant antibody development represents a high risk of endothelial corneal allograft reactions.
Roy
R
R
Centre de Recherche en Inflammation, Immunologie, et Rhumatologie, Le Centre Hospitalier, Université Laval, Québec, Canada.
Boisjoly
H M
HM
Wagner
E
E
Langlois
A
A
Bernard
P M
PM
Bazin
R
R
Laughrea
P A
PA
Dubé
I
I
D000906:Antibodies / Q000032:analysis*; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000502:physiology; D016039:Corneal Transplantation / Q000276:immunology*; D004728:Endothelium, Corneal / Q000276:immunology; D006082:Graft Enhancement, Immunologic; D006085:Graft Survival; D006801:Humans; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous
D000906:Antibodies; D000961:Antilymphocyte Serum